Endogenex

Endogenex is a clinical‑stage medical‑device company developing an endoscopic procedure that uses non‑thermal pulsed electric fields (PEF) in the duodenum to “reset” metabolic signaling and improve control of type 2 diabetes (T2D).[3][4]

High‑Level Overview

Endogenex is building the Endogenex System and the ReCET procedure: an endoscopically delivered PEF catheter intended to remove poorly functioning duodenal signaling cells and induce regeneration of healthier cells to improve glycemic control and slow T2D progression; the procedure is investigational and being evaluated in pivotal clinical studies.[4][3] The company was founded in partnership with Mayo Clinic and positions its therapy as a non‑pharmacologic, durable option complementary to current diabetes medicines, aiming to reduce medication dependence and alter disease trajectory for people with T2D.[3][2]

Origin Story

Endogenex was founded in partnership with Mayo Clinic to translate research on duodenal signaling and metabolic regulation into a therapeutic platform for T2D.[3] Key clinical inventors include physicians such as Barham Abu Dayyeh, M.D., M.P.H., who has been cited as a co‑inventor on the technology.[3] The company advanced through preclinical work into human studies and most recently closed an $88 million Series C to complete the pivotal ReCET clinical trial after receiving an IDE for the study.[2][1]

Core Differentiators

• Novel mechanism: Uses *non‑thermal pulsed electric field* energy applied endoscopically to the duodenal mucosa/submucosa to ablate dysfunctional signaling cells and trigger regenerative processes rather than systemic drug action.[4]
  - Endoscopic delivery: Procedure is minimally invasive (endoscopic catheter), leveraging existing therapeutic endoscopy infrastructure and expertise.[4]
  - Clinical partnership and data focus: Founded with Mayo Clinic collaboration and advancing a pivotal ReCET trial under an FDA investigational device exemption.[3][2]
  - Financing/validation: Recent oversubscribed $88M Series C with strategic and healthcare investors (including Intuitive Ventures, Longitude Capital, Lumira Ventures, Hatteras, Mayo Clinic) signals investor confidence in the clinical pathway and commercial potential.[2][1]

Role in the Broader Tech/Medical Landscape

Endogenex is riding two converging trends: increasing interest in device‑based metabolic interventions (duodenal therapies to modulate gut‑driven metabolic signaling) and a push for durable, non‑drug options to address the global T2D burden.[3][4] Timing matters because T2D prevalence remains large and costly worldwide, and while GLP‑1 and SGLT2 therapies address outcomes, there is demand for treatments targeting underlying pathophysiology and disease progression.[3] If the ReCET pivotal data support safety and durable efficacy, Endogenex could influence clinical practice by adding an interventional option that complements pharmacotherapy and bariatric approaches, and by accelerating investment in endoscopic metabolic therapies.[2][4]

Quick Take & Future Outlook

Near term, Endogenex’s trajectory depends on successful completion and positive readout from the pivotal ReCET study and subsequent regulatory review to gain market authorization.[2][4] Longer term, trends that will shape its journey include payer acceptance of device‑based metabolic interventions, real‑world durability versus medical therapy, comparative effectiveness versus other endoscopic/metabolic procedures, and integration into endocrinology and gastroenterology care pathways.[3][4] If clinical outcomes demonstrate meaningful, durable glycemic control with acceptable safety, Endogenex could become a notable non‑pharmacologic option for T2D and spur broader adoption of gut‑targeted metabolic therapies.[2][4]

If you’d like, I can:

• Summarize the ReCET trial design and IDE status in more detail,[2][4] or
• Compile the company’s public leadership, patent filings, and investor list into a one‑page brief.[1][2]